VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

VJVirtual | PRIME-HCC: ipilimumab and nivolumab in liver cancer

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, shares an update on the Phase Ib PRIME-HCC trial (NCT03682276) of neoadjuvant ipilimumab and nivolumab before liver resection in patients with hepatocellular cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter